Aligos Therapeutics Inc

Stock Chart, Company Information, and Scan Results

$7.65(as of Aug 10, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Aligos Therapeutics Inc Company Information, Fundamentals, and Technical Indicators

Stock Price$7.65
Ticker SymbolALGS
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees82
CountyUSA
Market Cap$34.9M

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifoscorvir sodium, a capsid assembly modulator, which is in Phase 2 B clinical trial; and ALG-097558, a small molecule ritonavir-free pan-coronavirus protease inhibitor which has completed a Phase 1 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Emory University; and Katholieke Universiteit Leuven. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Aligos Therapeutics Inc In Our Stock Scanner

As of Aug 10, 2026
As of ---
As of ---
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.